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Abstract—Heightened expression of the S100 calcium–binding protein, S100A4/Mts1, is observed in pulmonary vascular
disease. Loss of serotonin (5-hydroxytryptamine [5-HT]) receptors or of the serotonin transporter (SERT) attenuates
pulmonary hypertension in animals, and polymorphisms causing gain of SERT function are linked to clinical pulmonary
vascular disease. Because 5-HT induces release of S100, we investigated the codependence of 5-HT receptors and
SERT in regulating S100A4/Mts1 in human pulmonary artery smooth muscle cells (hPA-SMC). 5-HT elevated
S100A4/Mts1 mRNA levels and increased S100A4/Mts1 protein in hPA-SMC lysates and culture media. S100A4/Mts1
in the culture media stimulated proliferation and migration of hPA-SMC in a manner dependent on the receptor for
advanced glycation end products. Treatment with SB224289 (selective antagonist of 5-HT1B), fluoxetine (SERT
inhibitor), SERT RNA-interference, and iproniazid (monoamine oxidase-A inhibitor), blocked 5-HT–induced S100A4/
Mts1. 5-HT signaling mediated phosphorylation (p) of extracellular signal–regulated kinase 1/2 (pERK1/2), but
pERK1/2 nuclear translocation depended on SERT, monoamine oxidase activity, and reactive oxygen species. Nuclear
translocation of pERK1/2 was required for pGATA-4–mediated transcription of S100A4/Mts1. These data provide
evidence for a mechanistic link between the 5-HT pathway and S100A4/Mts1 in pulmonary hypertension and explain
how the 5-HT1B receptor and SERT are codependent in regulating S100A4/Mts1. (Circ Res. 2005;97:227-235.)
Key Words: smooth muscle cells  pulmonary hypertension  S100A4/Mts1  serotonin  ERK1/2
A
berrations in serotonin (5-hydroxytryptamine [5-HT])–
mediated signaling events have been linked to pulmo-
nary vascular disease (PVD).1,2 Studies in transgenic mice
indicate that both the serotonin transporter (SERT)2,3 and
5-HT receptors4–6 are necessary in the development of
pulmonary hypertension (PAH). An insertion/deletion poly-
morphism in the SERT promoter, resulting in 2- to 3-fold
higher levels of SERT gene transcription, has been observed
in 65% of idiopathic PAH (IPAH) versus 27% of control
patients.7 Additional studies have shown that patients using
the anorectic drug dexfenfluramine, a 5-HT uptake inhibitor
and SERT substrate that results in increased circulating 5-HT
levels and exaggerated receptor signaling,8 have a 23-fold
increased risk of developing IPAH.9 Similarly, patients with
abnormal 5-HT platelet storage and elevated circulating 5-HT
levels10 similar to the Fawn-hooded rat,11 are at increased risk
of developing PAH.
A recent study has linked SERT-mediated phosphorylation
of ERK1/2 to phosphorylation of the transcription factor
GATA-4 and to heightened expression of cyclin D2, a gene
expressed in proliferating cells.12 Transport of serotonin via
SERT results in monoamine oxidase-A (MAO-A) activity,
necessary for Rho kinase (ROCK)-mediated nuclear translo-
cation of ERK1/2.13 How SERT interacts with 5-HT receptor
signaling in regulating genes specifically associated with
PVD has not been addressed.
In astrocytes, 5-HT mediates the release of S100,a
member of the S100 family of small calcium-binding pro-
teins.14 We recently reported heightened expression of an-
other S100 family member, S100A4/Mts1, in human pulmo-
nary artery smooth muscle cells (hPA-SMC) within the
neointima and adventitia of occlusive lesions in patients with
grade III to IV PVD.15 Additionally, 5% of transgenic mice
ubiquitously overexpressing S100A4/Mts1 develop occlusive
pulmonary arterial lesions similar to those seen in patients
with PVD.15 S100A4/Mts1 has also been implicated in the
heightened proliferation and motility of cancer cells,16 in
angiogenesis17 and endothelial cell invasion,18 and in epithe-
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227lial–mesenchymal transformation in the lung.19 A specific
S100A4/Mts1 receptor had not been defined. However,
S100 mediates neurite outgrowth through the receptor for
advanced glycation end products (RAGE).20 RAGE is up-
regulated in vascular disease21 and is expressed on both
endothelial and SMC surfaces.20
These observations led us to hypothesize that 5-HT recep-
tors and SERT cooperatively mediate signaling pathways
required for gene expression and release of S100A4/Mts1,
which, in turn, binds to RAGE, leading to vascular cell
migration and proliferation, features associated with progres-
sive PVD.
Materials and Methods
Cell Culture and Functional Assays
Before stimulation with 5-HT (Sigma Aldrich, St Louis, Mo),
hPA-SMC (described in the online data supplement available at
http://circres.ahajournals.org) were incubated in DMEM containing
penicillin, streptomycin, amphotericin B solution and 0.2% FBS for
48 hours. Pretreatment with all inhibitors was performed for 30
minutes before 5-HT stimulation. Cell proliferation was assessed
using the 3-(4,5-dimethylthiazol-2)-2,5-diphenyltetrazolium bro-
mide (MTT) assay (American Type Culture Collection) and con-
firmed by Coulter Counting; measurement of migration was per-
formed using a Boyden chamber assay as previously described.22
Conditioned media were concentrated using YM-3 filters (Chemi-
con, Temecula, Calif).
5-HT- and S100A4/Mts1-Related Reagents
5-HT- and S100A4/Mts1-related reagents are described in the online
data supplement.
TaqMan RT-PCR
RNA was isolated with Trizol (Invitrogen, Carlsbad, Calif) from
hPA-SMC or lung tissue and reverse transcribed using Superscript II
(Invitrogen). Real-time polymerase chain reaction (PCR) was per-
formed on a 7900HT Sequence Detection System with TaqMan
Figure 1. 5-HT induces S100A4/Mts1 (Mts1) expression and release. Human PA-SMC were serum starved for 48 hours before stimula-
tion with 10 mol/L 5-HT. A, Representative Western immunoblot (top) and densitometric analysis (bottom) of S100A4/Mts1 (11 kDa)
protein in cell lysates following stimulation with increasing concentrations of 5-HT for 24 hours. B, S100A4/Mts1 mRNA levels were
measured by TaqMan PCR and normalized to 2-microglobulin (2M) using the comparative CT method. C, Representative Western im-
munoblot (top) and densitometric analysis (bottom) of S100A4/Mts1 (11 kDa) protein in cell lysates. Densitometry values are normalized
to tubulin (50 kDa) as a loading control and expressed as a fold-increase over unstimulated cells at 0 hour. D, Secreted levels of
S100A4/Mts1 (11 kDa) protein in concentrated CM at 24 hours, relative to control. Bars represent meanSEM from 4 different experi-
ments. *P0.05 vs non–5-HT–treated control cells.
228 Circulation Research August 5, 2005Assays on Demand gene expression probes (system and probes from
Applied Biosystems, Foster City, Calif) for S100A4/Mts1 (human:
assay ID Hs00243201_m1; mouse: assay ID Mm00803372_g1),
SERT (assay ID Hs00169010_m1), and GATA-4 (assay ID
Hs00171403_m1) using the comparative delta-CT method with
2-microglobulin as the endogenous control.
Western Immunoblots, Immunoprecipitation,
and ELISA
Cell lysates and nuclear and cytoplasmic extracts were prepared for
Western immunoblots as described in the online data supplement.
Analysis of ERK1/2 phosphorylation by ELISA was performed
using antibodies recognizing ERK1/2 pERK1/2 (pTpY185/187) and
ERK1/2 (total) (Biosource International).
Immunofluorescence and Confocal Microscopy
hPA-SMC were seeded into 8-well chamber slides at 510
3 cells per
well and stimulated as described above. The cells were fixed using
3% (weight/volume) paraformaldehyde before incubation with
monoclonal mouse anti–phosphorylated ERK1/2 antibody (1:400)
(Cell Signaling Technologies). Immunofluorescent detection was
performed as described on the online data supplement.
Lentiviral Overexpression System
To overexpress human SERT, the full-length cDNA (a kind gift from
Dr R. Blakely, Vanderbilt University, Nashville, Tenn), was cloned
into the pLenti6/V5 expression plasmid via the Directional TOPO
Cloning kit (Invitrogen). Lentivirus was propagated and cells trans-
fected as described in the online data supplement. SERT expression
was monitored at 48 hours by Western immunoblot and quantitative
RT-PCR.
RNA-Interference Transfections
RNA-interference was induced by transient transfection using 100
nmol/L short-interfering RNA (siRNA) oligonucleotides complexed
Figure 2. Conditioned media from 5-HT–stimulated cells
induces proliferation and migration of hPA-SMC via S100A4/
Mts1 and RAGE. Human PA-SMC were serum starved for 48
hours before stimulation with 10 mol/L 5-HT, and CM was col-
lected after 24 hours for the proliferation and migration studies.
A, Cells were stimulated with 10 ng/mL PDGF-BB or 500 ng/mL
rMts1 in the presence or absence of sRAGE. Cell counts were
performed by Coulter Counter 48 hours after stimulation. B,
Cells were stimulated with 10 ng/mL PDGF-BB, 500 ng/mL
recombinant S100A4/Mts1 (rMts1), or CM (5-HT CM). To block
RAGE, cells or the CM were preincubated with an anti-RAGE
antibody or with sRAGE, and, to speciﬁcally neutralize S100A4/
Mts1, an anti-S100A4/Mts1 antibody (1.25 ng/mL) was used.
Proliferation was measured using the MTT assay and normal-
ized relative to control, unstimulated cells at 24 hours. C, Cells
were treated as in B, migration was measured at 6 hours using
a Boyden Chamber assay, and cells were normalized relative to
control, unstimulated cells. Bars represent meanSEM from 4
different experiments. ***P0.0001 compared with non–5-HT
serum-free control cells (SF), P0.01 and P0.001
relative to stimulated control. Inc. indicates increase.
Figure 3. SERT overexpression further enhances S100A4/Mts1
expression. Human PA-SMC were infected with pLenti-hSERT
or pLenti-lacZ before serum starvation and simulation with
10 mol/L 5-HT. A, Representative Western immunoblot (top)
and densitometric analysis (bottom) of SERT protein (70 kDa)
normalized to tubulin (50 kDa). B, Representative Western im-
munoblot (top) and densitometric analysis (bottom) of S100A4/
Mts1 (Mts1) protein (11 kDa) expression normalized to tubulin
(50 kDa). C, S100A4/Mts1 (Mts1) mRNA isolated from the lungs
of SERT overexpressing transgenic mice (5-HTT/), measured
by TaqMan PCR (normalized to the 18S ribosomal RNA using
the comparative CT method) when compared with nontransgenic
littermate controls. Bars represent meanSEM from 4 replicate
experiments in A and B and from 4 transgenic and 5 littermate
control mice in C. *P0.05 compared with non–5-HT–treated
pLenti-lacZ control cells, **P0.01 compared with littermate
controls, #P0.05 compared with non–5-HT–treated SERT con-
trol. Inc. indicates increase.
Lawrie et al 5-HT1B Receptor and SERT Regulate S100A4/Mts1 229with Lipofectamine 2000 (Invitrogen) according to the instructions
of the manufacturer. The design of the oligonucleotides is given in
the online data supplement.
Statistical Analyses
Statistical analysis was performed using a repeated-measure
ANOVA followed by the Newman–Keuls post hoc test with a 95%
confidence level where P0.05 was deemed statistically significant.
Results
5-HT Induces S100A4/Mts1 Expression
and Release
Quiescent hPA-SMC were stimulated for 24 hours with a
dose range of 0.001 to 10 mol/L 5-HT.23,24 A significant
elevation in S100A4/Mts1 mRNA level was seen at
10 mol/L, although incremental trends were apparent with
all the lower doses (Figure 1A); 10 mol/L 5-HT was used in
all subsequent studies. The S100A4/Mts1 mRNA level, as
measured by TaqMan PCR, was increased by 6 hours
following 5-HT stimulation, with the maximal response
(3-fold) seen at 24 hours (Figure 1B). A comparable
increase in S100A4/Mts1 protein was documented at the
same time points by densitometric evaluation of Western
immunoblots from whole cell lysates (Figure 1C). The level
of S100A4/Mts1 protein in concentrated conditioned media
(CM) 24 hour following 5-HT stimulation, was similarly
increased relative to unstimulated control cells (Figure 1D).
Conditioned Medium From 5-HT–Stimulated Cells
Induces Proliferation and Migration of PA-SMC
via S100A4/Mts1 and RAGE
An increase in cell counts 48 hours following stimulation
with 500 ng/mL recombinant S100A4/Mts1 (rS100A4/Mts1)
was repressed by preincubation with a soluble form of RAGE
(sRAGE) (2.5 g/mL), in contrast to a similar degree of cell
proliferation achieved with 10 ng/mL platelet-derived growth
factor (PDGF) (Figure 2A). CM collected from PA-SMC 24
hours after 5-HT stimulation were added to serum-starved
PA-SMC and induced a 7-fold increase in proliferation,
similar to that achieved following stimulation with 10 ng/mL
PDGF-BB or 500 ng/mL recombinant S100A4/Mts1
(rS100A4/Mts1) as judged by the MTT assay at 24 hours.
Preincubation of the CM with sRAGE (2.5 g/mL) or
preincubation of the cells with an anti-RAGE (1.25 g/mL)
or anti-S100A4/Mts1 antibody (1.25 g/mL) reduced the
proliferation observed in response to rS100A4/Mts1 or to the
CM from 5-HT stimulated cells but had no effect on the PDGF-BB
mediated response (Figure 2B). Similar results were observed
when we examined the effect of CM from 5-HT–stimulated
hPA-SMC on hPA-SMC migration assessed in Boyden
chamber assays (Figure 2C). These studies indicated that
5-HT–mediated production and release of S100A4/Mts1 in-
duce proliferation and migration of hPA-SMC in a RAGE-
dependent fashion.
5-HT induced SERT expression in pLenti-lacZ cells and
further increased SERT expression in cells infected with
pLenti-hSERT (Figure 3A). This correlated with an elevated
S100A4/Mts1 protein level in the cell lysates of pLenti-
hSERT–infected cells (Figure 3B) and a further increase
following stimulation with 5-HT (Figure 3B). S100A4/Mts1
mRNA measured by TaqMan PCR in lungs of transgenic
mice overexpressing human SERT (5HTT
/)2 was increased
2-fold compared with littermate controls (Figure 3C).
SERT and 5-HT Receptors Are Both Required for
5-HT–Induced S100A4Mts1 Expression
Human PA-SMC transfected with siRNA oligonucleotides tar-
geting SERT reduced levels by 90% as measured by TaqMan
RT-PCR at 48 hours (data not shown) and to barely detectable
levels in cell lysates 72 hours posttransfection (Figure 4A). 5-HT
stimulation of the SERT siRNA–transfected cells failed to
increase S100A4/Mts1 expression, in contrast to control hPA-
SMC or cells transfected with a scrambled SERT siRNA
sequence or a nonsilencing siRNA oligonucleotide encoding
luciferase (Figure 4B). Further experiments showed that inhibi-
Figure 4. SERT and 5-HT receptors are both required for 5-HT–induced S100A4/Mts1 expression. A and B, hPA-SMC were transfected
with 100 nmol/L scrambled siRNA (SCR si), luciferase siRNA (Luc si), or SERT siRNA (SERT si) oligos and serum starved for 48 hours
before stimulation with serum for 24 hours. A, Representative Western immunoblot of SERT protein (70 kDa) following siRNA transfec-
tion. Ctrl indicates control. B, Representative Western immunoblot (top) and densitometric analysis (bottom) of S100A4/Mts1 (Mts1)
protein (11 kDa). C, 5-HT–mediated S100A4/Mts1 (Mts1) (11 kDa) expression in cells treated with 10 mol/L ﬂuoxetine (Fluo), a SERT
inhibitor, 10 mol/L ketanserin (Ket), a 5-HT receptor antagonist, and 0.1 mmol/L iproniazid (IPR), an MAO inhibitor, and with DMSO
(vehicle) alone. D, 5-HT–induced increase in S100A4/Mts1 protein expression in cell lysates is not blocked by ketanserin at 0.1 mol/L
(selective for 5-HT2A) but is reduced by 1 mol/L and 10 mol/L (likely to antagonize 5-HT2A, 5-HT2B, and 5-HT1B). This response is not
blocked by 0.2 mol/L SB204741 (selective for 5-HT2B; Sigma) but is blocked by 0.1 mol/L SB224289 (selective for 5-HT1B; Sigma).1
Bars represent meanSEM from 4 replicate experiments, normalized as described in Figure 1. *P0.05 vs non–5-HT–treated control
cells. Ctrl indicates control; Inc., increase.
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S100A4/Mts1 in response to 5-HT (Figure 4C). Inhibition of
MAO-A with iproniazid demonstrated that suppression of events
downstream of SERT, such as 5-HT breakdown by MAO-A
activity,26 also prevented induction of S100A4/Mts1 in response
to 5-HT (Figure 4C). A similar inability of 5-HT to induce
production of S100A4/Mts1 was observed by blocking 5-HT
receptors with ketanserin23 (Figure 4C), and selective inhibitors
revealed the specific involvement of the 5HT1B receptor in
mediating production of S100A4/Mts1. Figure 4D shows that
the 5-HT–induced increase in S100A4/Mts1 protein expression
in cell lysates is not blocked by ketanserin at 0.1 mol/L
(selective for 5-HT2A) but is reduced by 1 mol/L and
10 mol/L (likely to antagonize 5-HT2A, 5-HT2B, and 5-HT1B).
This response is not blocked by 0.2 mol/L SB204741 (selec-
tive for 5-HT2B; Sigma) but is blocked by 0.1 mol/L SB224289
(Sigma, selective for 5-HT1B) (Figure 4D).6
5-HT Receptor–Mediated ERK1/2 Phosphorylation
Is Necessary to Induce S100A4/Mts1
Serotonin-mediated ERK1/2 phosphorylation (pERK) has
been implicated in the induction of genes involved in SMC
proliferation, such as cyclin D2.12 In keeping with these
observations, concurrent treatment with 5-HT and the pERK
inhibitor PD98059 (100 mol/L) prevented the induction of
S100A4/Mts1 mRNA (Figure 5A) and protein in cell lysates
(Figure 5B) compared with treatment with 5-HT alone. A
4-fold increase in pERK was observed 5 minutes after 5-HT
(10 mol/L) stimulation, as assessed by ELISA and verified
by Western immunoblot (Figure 5C). This increase in pERK
was blocked by the 5-HT receptor antagonist ketanserin, but
not by inhibitors of SERT (fluoxetine) or MAO-A activity
(iproniazid), when compared with treatment with vehicle
alone (DMSO) (Figure 5C).
The antibody used in the pERK ELISA identified tyrosine/
threonine phosphorylation at amino acids 185/187. To rule
out the possibility that the SERT pathway initiates phospho-
rylation of an alternate site, at amino acids 202/204, we
compared our findings by ELISA with those on Western
immunoblot using a monoclonal antibody recognizing
pERK202/204, but results were similar (Figure 5D).
Blockade of SERT and MAO Reduces the Nuclear
Translocation of pERK1/2
We therefore determined whether SERT, MAO-A activity, or
generation of reactive oxygen species (ROS) mediate
pERK1/2 nuclear translocation. Following 5-HT stimulation,
pERK was significantly increased in the nuclear fraction
(Figure 6), but this was prevented following treatment with
fluoxetine, ketanserin, iproniazid, and the free radical (ROS)
scavenger N-acetyl cysteine (NAC) (Figure 6A). No cytoplas-
mic pERK remained following 5-HT treatment alone or with
the inhibitor vehicle (DMSO), consistent with nuclear trans-
location (Figure 6B), but treatment with fluoxetine, ipronia-
zid, or NAC resulted in persistent pERK in the cytoplasmic
extracts (Figure 6B). Ketanserin, the 5-HT receptor blocker,
repressed pERK in both nuclear and cytoplasmic fractions.
Immunofluorescent staining of hPA-SMC provided further
evidence that a signal from the 5-HT receptor causes phos-
phorylation of ERK1/2 and that SERT, MAO-A, and ROS-
mediated events result in nuclear translocation of pERK
(Figure 6C). Clear punctuate nuclear localization of pERK1/2
was observed following stimulation with 5-HT compared
with unstimulated control cells. Inhibition of SERT and
MAO-A (fluoxetine and iproniazid, respectively) reduced the
nuclear translocation of pERK1/2, with enhanced cytoplas-
mic pERK1/2 evident. Little nuclear pERK1/2 was observed
in cells treated with either the 5-HT receptor antagonist
ketanserin (Figure 6C) or with PD98059 (data not shown).
Phosphorylation of GATA-4 Is Required for
5-HT–Induced S100A4/Mts1 Expression
Serotonin-induced expression of cyclin D2 in PA-SMC has
been previously attributed to pERK-mediated phosphoryla-
tion of the transcription factor GATA-4,12 and analysis of the
promoter region of the S100A4/Mts1 gene revealed a
GATA-4 binding site. We, therefore, used siRNA-targeting
Figure 5. 5-HT receptor–mediated ERK1/2 phosphorylation is
necessary to induce S100A4/Mts1 expression. A, hPA-SMC
were treated with the ERK1/2 inhibitor PD98059 (100 mol/L),
and 5-HT–mediated S100A4/Mts1 (Mts1) mRNA expression was
measured by TaqMan PCR. B, Representative Western immuno-
blot (top) and densitometric analysis (bottom) of S100A4/Mts1
(Mts1) protein (11 kDa) in cell lysates assessed by Western im-
munoblot, as described in Figure 1. C, Analysis of pERK1/2
185/187 was performed by ELISA normalized to an additional
ELISA measurement of total ERK1/2 following 10 mol/L 5-HT
stimulation in the presence of 10 mol/L ﬂuoxetine (Fluo),
10 mol/L ketanserin (Ket), and 0.1 mmol/L iproniazid (IPR). D,
Representative immunoblot of pERK1/2 202/204 and tERK1/2
(both p44 and p42 isoforms are seen) shows a pattern of phos-
phorylation in keeping with C. Bars represent meanSEM from
4 replicate experiments normalized as in Figure 1. *P0.05 vs
non–5-HT–treated controls, #P0.05 vs 5-HT–treated controls.
Ctrl indicates control; Inc., increase.
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mRNA (data not shown) and pGATA-4 protein (Figure 7A).
We subsequently showed that this level of reduction in
GATA-4 prevented 5-HT–induced S100A4/Mts1 expression
in cell lysates (Figure 7B). 5-HT–induced phosphorylation of
GATA-4 was blocked with ketanserin, as well as with
fluoxetine, iproniazid, and the inhibitor of pERK1/2,
PD98059 (Figure 7C).
Discussion
There is an increase in a SERT polymorphism in PAH
patients7 that results in SERT overexpression, and 5-HT
receptor and SERT knockout transgenic mice are equally
protected against the development of PAH.3,4 This study
shows how a 5-HT receptor and SERT cooperatively interact
to regulate S100A4/Mts1, a gene induced in clinical PAH.15
The use of selective 5-HT receptor blockers identified the
5-HT1B receptor as involved in the regulation of S100A4/
Mts1, and this receptor has been implicated in PAH.6,27–29
S100A4/Mts1, secreted into the media following 5-HT
stimulation, can facilitate both the proliferation and migration
of hPA-SMC in a manner dependent on the receptor, RAGE.
Heightened stimulation of S100A4/Mts1 occurs when the
level of SERT is increased in hPA-SMC cultures and in a
transgenic mouse. Although 5-HT receptor activity is re-
quired for phosphorylation of ERK, nuclear transport of
phosphorylated ERK depends on SERT, MAO-A activity,
and ROS production in these hPA-SMC. Nuclear transloca-
Figure 6. Blockade of SERT and MAO reduces nuclear translocation of ERK1/2. Human PA-SMC were stimulated with 5-HT in combi-
nation with inhibitors as described in Figure 5 before isolation of both nuclear and cytoplasmic fractions. As in Figure 5, cells were har-
vested 5 minutes after 5-HT stimulation. A, pERK (both p44 and p42 isoforms, as indicated) in the nuclear fractions following 5-HT
treatment alone or in combination with vehicle (DMSO) or treatment with 10 mol/L ﬂuoxetine (Fluo), 0.1 mmol/L ipronaizid (IPR), the
ERK1/2 inhibitor PD98059 (PD), or 1 mmol/L NAC. B, Cytoplasmic pERK under the conditions described in A. Bars represent
meanSEM from 3 replicate experiments normalized as in Figure 1. *P0.05 vs non–5-HT–treated controls. C, Immunoﬂuorescence
viewed at 100 magniﬁcation (Bar10 m), and representative of 3 different experiments, shows clear punctuate nuclear localization of
pERK1/2 following stimulation with 5-HT compared with control cells. Treatment with 10 mol/L ﬂuoxetine (Fluo) or 0.1 mmol/L ipronia-
zid (IPR) reduced the nuclear translocation with more cytoplasmic pERK1/2 evident. Little nuclear pERK1/2 was observed in cells
treated with 10 mol/L ketanserin (Ket). Ctrl indicates control; Inc., increase.
232 Circulation Research August 5, 2005tion of pERK is necessary for phosphorylation of GATA-4, a
transcription factor required for expression of S100A4/Mts1,
in response to 5-HT. A diagram of this proposed model is
shown in Figure 8.
The mitotic and vasconstrictive roles of 5-HT in PA-SMC
have been well documented,1,5,6,26,30 and recent work has
highlighted the regulation of genes specific to cell cycle
progression12 but not those selectively identified with disease.
Although previous studies have shown that the 5-HT pathway
can regulate other members of the S100 family,14 we now
present an intriguing link between 5-HT and PVD through the
induction of S100A4/Mts1 gene expression. We recognize
that the concentration of 5-HT that produced a significant
increase in S100A4/Mts1 was higher than circulating levels,
but local concentrations could also be higher when released
from platelets, neuropithelial cells, and mast cells. In addi-
tion, the availability of SERT would limit the intracellular
accumulation of 5-HT to within physiological levels. Previ-
ous studies have shown that a small subset of transgenic mice
that overexpress S100A4/Mts1 have PVD15 and that in-
creased expression of S100A4/Mts1 is localized to the neo-
intima in advanced PVD lesions.15 We did not detect
S100A4/Mts1 expression in human PA endothelial cells in
those studies, but its ability to stimulate proliferation and
migration of PA endothelial cells17,18 may also be relevant to
the pathology of PVD.31
Expression of RAGE is increased in cancer,32 as well as in
atherosclerosis,33 restenosis,34 and diabetic vasculopathy.35
Our studies show that RAGE is necessary for S100A4/Mts1-
mediated effects in hPA-SMC and are in keeping with RAGE
being the receptor for this ligand in these cells. Other studies
by our group, in which RAGE coimmunoprecipitates with
S100A4/Mts1 in hPA-SMC lysates, reinforce this concept
(data not shown).
Because heightened expression of S100A4/Mts1 in re-
sponse to 5-HT is observed when SERT is overexpressed, it
would be interesting to investigate whether enhanced
S100A4/Mts1 expression is linked to patients with the in-
creased incidence of the SERT polymorphism associated with
heightened serotonin transport.
It has previously been shown in bovine PA-SMC that 5-HT
transport via SERT results in the production of ROS includ-
ing both superoxide36 and H2O2.37 Recent studies in cardiac
myocytes have suggested that intracellular 5-HT metabolism
by MAO-A is necessary for the generation of ROS.38 Other
studies show that stimulation of cells with 5-HT can induce
ROS via NADPH oxidase.39 We established that phosphory-
lation of ERK1/2 is required for 5-HT–mediated S100A4/
Mts1 production in hPA-SMC and is specifically related to
the activity of the 5-HT1B receptor. The signal necessary for
nuclear translocation of pERK comes via SERT, MAO-A
activity, and ROS40 production. These observations are in
keeping with studies by Greene et al23 and Grewal et al24 but
differ from those of Fanburg and coworkers,12,41–43 who
proposed that ERK phosphorylation occurs via SERT-
mediated ROS production. These discrepancies may be ex-
plained by differences in expression of the 5-HT receptor
subtypes among species and cell type (reviewed by Hoyer et
al44), as documented by Lee et al.36
Figure 7. Phosphorylation of GATA-4 is required for 5-HT–in-
duced S100A4/Mts1 expression. Human PA-SMC were trans-
fected with 100 nmol/L cyclophilin B (Cyclo si), luciferase (LUC
si), or GATA-4 siRNA oligonucleotides. A, Representative West-
ern immunoblot of pGATA-4 (46 kDa) in control and siRNA
treated hPA-SMC. B, Representative Western immunoblot (top)
and densitometric evaluation (bottom) of S100A4/Mts1 protein
(11 kDa), as in A. C, Representative Western immunoblot (top)
of pGATA-4 (46 kDa) and densitometric analysis (bottom) 6
hours following 10 mol/L 5-HT stimulation and treatment with
10 mol/L ketanserin (Ket), 10 mol/L ﬂuoxetine (Fluo),
0.1 mmol/L iproniazid (IPR), or 100 mol/L PD98059 (PD). Bars
represent meanSEM from 4 replicate experiments normalized
as in Figure 1. *P0.05 vs non–5-HT–treated controls. Ctrl indi-
cates control; Inc., increase.
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localization of serum response factor28 and facilitate the
nuclear translocation of pERK1/2 in bovine PA-SMC in a
manner dependent on ROS.13 How ROS mediate nuclear
translocation of pERK1/2 remains to be determined. It is
possible that ROS modify a protein such as Sef (similar
expression to fgf genes)45 or apolipoprotein D that block
pERK1/2 nuclear translocation.46
Phosphorylation of GATA-4 following nuclear transloca-
tion of pERK1/2 was required for 5-HT induction of S100A4/
Mts1 expression. GATA-4 is an important transcription factor
in cardiac development, hypertrophic responses, and in the
formation of coronary arteries,47,48 but the role of cardiac
myocyte expression of S100A4/Mts149 in these processes has
not been investigated. It is also possible that other stimuli,
such as endothelin-150 or 1-adrenergic agonists,51 that lead to
the phosphorylation of GATA-4 at serine 105 via the MEK/
ERK pathway may regulate S100A4/Mts1.
Mutations in bone morphogenetic protein receptor II have
been linked to a heightened risk of developing PVD in
patients with IPAH,52 but only 20% of affected family
members succumb to the disease. Although loss of bone
morphogenetic protein receptor II does not further induce
5-HT–mediated S100A4/Mts1 production (our unpublished
data), it may enhance the cellular effects of S100A4/Mts1.
Our results, in showing the interdependency of events medi-
ated by the 5-HT1B receptor and by SERT, suggest that
inhibition of either pathway may be sufficient to block the
development of experimental PAH and PVD.
Acknowledgments
This work was supported by NIH grant 1-R01-HL074186-01 (to
M.R.) and the Dwight and Vera Dunlevie Endowed Professorship (to
M.R.). A.L. was supported, in part, by a Dean’s Fellowship from
Stanford University School of Medicine.
References
1. Marcos E, Fadel E, Sanchez O, Humbert M, Dartevelle P, Simonneau G,
Hamon M, Adnot S, Eddahibi S. Serotonin-induced smooth muscle
hyperplasia in various forms of human pulmonary hypertension. Circ
Res. 2004;94:1263–1270.
2. MacLean MR, Deuchar GA, Hicks MN, Morecroft I, Shen S, Sheward J,
Colston J, Loughlin L, Nilsen M, Dempsie Y, Harmar A. Overexpression
of the 5-hydroxytryptamine transporter gene: effect on pulmonary hemo-
dynamics and hypoxia-induced pulmonary hypertension. Circulation.
2004;109:2150–2155.
3. Eddahibi S, Hanoun N, Lanfumey L, Lesch KP, Raffestin B, Hamon M,
Adnot S. Attenuated hypoxic pulmonary hypertension in mice lacking the
5-hydroxytryptamine transporter gene. J Clin Invest. 2000;105:
1555–1562.
4. Launay JM, Herve P, Peoc’h K, Tournois C, Callebert J, Nebigil CG,
Etienne N, Drouet L, Humbert M, Simonneau G, Maroteaux L. Function
of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hyper-
tension. Nat Med. 2002;8:1129–1135.
5. MacLean MR, Morecroft I. Increased contractile response to 5-hydroxy-
tryptamine1-receptor stimulation in pulmonary arteries from chronic
hypoxic rats: role of pharmacological synergy. Br J Pharmacol. 2001;
134:614–620.
6. Morecroft I, Heeley RP, Prentice HM, Kirk A, MacLean MR. 5-hydroxy-
tryptamine receptors mediating contraction in human small muscular
pulmonary arteries: importance of the 5-HT1B receptor. Br J Pharmacol.
1999;128:730–734.
7. Eddahibi S, Humbert M, Fadel E, Raffestin B, Darmon M, Capron F,
Simonneau G, Dartevelle P, Hamon M, Adnot S. Serotonin transporter
overexpression is responsible for pulmonary artery smooth muscle hyper-
plasia in primary pulmonary hypertension. J Clin Invest. 2001;108:
1141–1150.
8. Eddahibi S, Adnot S, Frisdal E, Levame M, Hamon M, Raffestin B.
Dexfenfluramine-associated changes in 5-hydroxytryptamine transporter
expression and development of hypoxic pulmonary hypertension in rats.
J Pharmacol Exp Ther. 2001;297:148–154.
9. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X,
Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Begaud
B. Appetite-suppressant drugs and the risk of primary pulmonary hyper-
tension. International Primary Pulmonary Hypertension Study Group.
N Engl J Med. 1996;335:609–616.
10. Herve P, Drouet L, Dosquet C, Launay JM, Rain B, Simonneau G, Caen
J, Duroux P. Primary pulmonary hypertension in a patient with a familial
platelet storage pool disease: role of serotonin. Am J Med. 1990;89:
117–120.
11. Sato K, Webb S, Tucker A, Rabinovitch M, O’Brien RF, McMurtry IF,
Stelzner TJ. Factors influencing the idiopathic development of pulmonary
hypertension in the fawn hooded rat. Am Rev Respir Dis. 1992;145:
793–797.
12. Suzuki YJ, Day RM, Tan CC, Sandven TH, Liang Q, Molkentin JD,
Fanburg BL. Activation of GATA-4 by serotonin in pulmonary artery
smooth muscle cells. J Biol Chem. 2003;278:17525–17531.
13. Liu Y, Suzuki YJ, Day RM, Fanburg BL. Rho kinase-induced nuclear
translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused
by serotonin. Circ Res. 2004;95:579–586.
14. Whitaker-Azmitia PM, Azmitia EC. Astroglial 5-HT1a receptors and
S-100 beta in development and plasticity. Perspect Dev Neurobiol. 1994;
2:233–238.
15. Greenway S, van Suylen RJ, Du Marchie Sarvaas G, Kwan E,
Ambartsumian N, Lukanidin E, Rabinovitch M. S100A4/Mts1 produces
murine pulmonary artery changes resembling plexogenic arteriopathy and
is increased in human plexogenic arteriopathy. Am J Pathol. 2004;164:
253–262.
Figure 8. Schema describing coopera-
tive interaction between 5-HT1B receptor
and SERT in mediating S100A4/Mts1
expression and cellular sequelae. 5-HT–
induced expression of S100A4/Mts1
requires interdependent signals from the
5-HT1B receptor and SERT. The 5-HT1B
receptor mediates the phosphorylation of
ERK in response to 5-HT, whereas 5-HT
transport, via SERT, MAO-A activity, and
production of free radicals (ROS), allow
the translocation of pERK to the nucleus.
Once in the nucleus, pERK phosphory-
lates GATA-4, which leads to S100A4/
Mts1 expression. S100A4/Mts1 is
secreted from the cell, where it then
interacts with RAGE to mediate prolifera-
tion and migration of PA-SMC.
234 Circulation Research August 5, 200516. Ambartsumian N, Klingelhofer J, Grigorian M, Karlstrom O, Sidenius N,
Georgiev G, Lukanidin E. Tissue-specific posttranscriptional downregu-
lation of expression of the S100A4(mts1) gene in transgenic animals.
Invasion Metastasis. 1998;18:96–104.
17. Ambartsumian N, Klingelhofer J, Grigorian M, Christensen C, Kriajevska
M, Tulchinsky E, Georgiev G, Berezin V, Bock E, Rygaard J, Cao R, Cao
Y, Lukanidin E. The metastasis-associated Mts1(S100A4) protein could
act as an angiogenic factor. Oncogene. 2001;20:4685–4695.
18. Schmidt-Hansen B, Ornas D, Grigorian M, Klingelhofer J, Tulchinsky E,
Lukanidin E, Ambartsumian N. Extracellular S100A4(mts1) stimulates
invasive growth of mouse endothelial cells and modulates MMP-13
matrix metalloproteinase activity. Oncogene. 2004;23:5487–5495.
19. Okada H, Danoff TM, Kalluri R, Neilson EG. Early role of Fsp1 in
epithelial-mesenchymal transformation. Am J Physiol. 1997;273:
F563–F574.
20. Huttunen HJ, Kuja-Panula J, Sorci G, Agneletti AL, Donato R, Rauvala
H. Coregulation of neurite outgrowth and cell survival by amphoterin and
S100 proteins through receptor for advanced glycation end products
(RAGE) activation. J Biol Chem. 2000;275:40096–40105.
21. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for
advanced glycation end products: a mechanism for chronic vascular
dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res. 1999;
84:489–497.
22. Leung WC, Lawrie A, Demaries S, Massaeli H, Burry A, Yablonsky S,
Sarjeant JM, Fera E, Rassart E, Pickering JG, Rabinovitch M. Apoli-
poprotein D and platelet-derived growth factor-BB synergism mediates
vascular smooth muscle cell migration. Circ Res. 2004;95:179–186.
23. Greene EL, Houghton O, Collinsworth G, Garnovskaya MN, Nagai T,
Sajjad T, Bheemanathini V, Grewal JS, Paul RV, Raymond JR. 5-HT(2A)
receptors stimulate mitogen-activated protein kinase via H(2)O(2) gen-
eration in rat renal mesangial cells. Am J Physiol Renal Physiol. 2000;
278:F650–F658.
24. Grewal JS, Mukhin YV, Garnovskaya MN, Raymond JR, Greene EL.
Serotonin 5-HT2A receptor induces TGF-beta1 expression in mesangial
cells via ERK: proliferative and fibrotic signals. Am J Physiol. 1999;276:
F922–F930.
25. Eddahibi S, Raffestin B, Hamon M, Adnot S. Is the serotonin transporter
involved in the pathogenesis of pulmonary hypertension? J Lab Clin Med.
2002;139:194–201.
26. Lee SL, Wang WW, Moore BJ, Fanburg BL. Dual effect of serotonin on
growth of bovine pulmonary artery smooth muscle cells in culture. Circ
Res. 1991;68:1362–1368.
27. MacLean MR, Sweeney G, Baird M, McCulloch KM, Houslay M,
Morecroft I. 5-Hydroxytryptamine receptors mediating vasoconstriction
in pulmonary arteries from control and pulmonary hypertensive rats. Br J
Pharmacol. 1996;119:917–930.
28. Liu HW, Halayko AJ, Fernandes DJ, Harmon GS, McCauley JA,
Kocieniewski P, McConville J, Fu Y, Forsythe SM, Kogut P, Bellam S,
Dowell M, Churchill J, Lesso H, Kassiri K, Mitchell RW, Hershenson
MB, Camoretti-Mercado B, Solway J. The RhoA/Rho kinase pathway
regulates nuclear localization of serum response factor. Am J Respir Cell
Mol Biol. 2003;29:39–47.
29. Rondelet B, Van Beneden R, Kerbaul F, Motte S, Fesler P, McEntee K,
Brimioulle S, Ketelslegers JM, Naeije R. Expression of the serotonin 1b
receptor in experimental pulmonary hypertension. Eur Respir J. 2003;22:
408–412.
30. Eddahibi S, Fabre V, Boni C, Martres MP, Raffestin B, Hamon M, Adnot
S. Induction of serotonin transporter by hypoxia in pulmonary vascular
smooth muscle cells. Relationship with the mitogenic action of serotonin.
Circ Res. 1999;84:329–336.
31. Voelkel NF, Cool CD. Pulmonary vascular involvement in chronic
obstructive pulmonary disease. Eur Respir J Suppl. 2003;46:28s–32s.
32. Abe R, Shimizu T, Sugawara H, Watanabe H, Nakamura H, Choei H,
Sasaki N, Yamagishi S, Takeuchi M, Shimizu H. Regulation of human
melanoma growth and metastasis by AGE-AGE receptor interactions.
J Invest Dermatol. 2004;122:461–467.
33. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, Goova MT,
Moser B, Kislinger T, Lee DC, Kashyap Y, Stern DM, Schmidt AM.
RAGE blockade stabilizes established atherosclerosis in diabetic apoli-
poprotein E-null mice. Circulation. 2002;106:2827–2835.
34. Sakaguchi T, Yan SF, Yan SD, Belov D, Rong LL, Sousa M, Andrassy
M, Marso SP, Duda S, Arnold B, Liliensiek B, Nawroth PP, Stern DM,
Schmidt AM, Naka Y. Central role of RAGE-dependent neointimal
expansion in arterial restenosis. J Clin Invest. 2003;111:959–972.
35. Schmidt AM, Stern D. Atherosclerosis and diabetes: the RAGE con-
nection. Curr Atheroscler Rep. 2000;2:430–436.
36. Lee SL, Wang WW, Finlay GA, Fanburg BL. Serotonin stimulates
mitogen-activated protein kinase activity through the formation of
superoxide anion. Am J Physiol. 1999;277:L282–L291.
37. Lee SL, Simon AR, Wang WW, Fanburg BL. H(2)O(2) signals 5-HT-
induced ERK MAP kinase activation and mitogenesis of smooth muscle
cells. Am J Physiol Lung Cell Mol Physiol. 2001;281:L646–L652.
38. Bianchi P, Pimentel DR, Murphy MP, Colucci WS, Parini A. A new
hypertrophic mechanism of serotonin in cardiac myocytes: receptor-
independent ROS generation. FASEB J. 2005;19:641–643.
39. Liu JQ, Folz RJ. Extracellular superoxide enhances 5-HT-induced murine
pulmonary artery vasoconstriction. Am J Physiol Lung Cell Mol Physiol.
2004;287:L111–L118.
40. Vindis C, Seguelas MH, Lanier S, Parini A, Cambon C. Dopamine
induces ERK activation in renal epithelial cells through H2O2 produced
by monoamine oxidase. Kidney Int. 2001;59:76–86.
41. Lee SL, Wang WW, Fanburg BL. Association of Tyr phosphorylation of
GTPase-activating protein with mitogenic action of serotonin. Am J
Physiol. 1997;272:C223–C230.
42. Lee SL, Wang WW, Fanburg BL. Superoxide as an intermediate signal
for serotonin-induced mitogenesis. Free Radic Biol Med. 1998;24:
855–858.
43. Lee SL, Wang WW, Lanzillo JJ, Fanburg BL. Serotonin produces both
hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle
cells in culture. Am J Physiol. 1994;266:L46–L52.
44. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and func-
tional diversity of 5-HT receptors. Pharmacol Biochem Behav. 2002;71:
533–554.
45. Torii S, Kusakabe M, Yamamoto T, Maekawa M, Nishida E. Sef is a
spatial regulator for Ras/MAP kinase signaling. Dev Cell. 2004;7:33–44.
46. Sarjeant JM, Lawrie A, Kinnear C, Yablonsky S, Leung W, Massaeli H,
Prichett W, Veinot JP, Rassart E, Rabinovitch M. Apolipoprotein D
inhibits platelet-derived growth factor-BB-induced vascular smooth
muscle cell proliferated by preventing translocation of phosphorylated
extracellular signal regulated kinase 1/2 to the nucleus. Arterioscler
Thromb Vasc Biol. 2003;23:2172–2177.
47. Crispino JD, Lodish MB, Thurberg BL, Litovsky SH, Collins T,
Molkentin JD, Orkin SH. Proper coronary vascular development and
heart morphogenesis depend on interaction of GATA-4 with FOG
cofactors. Genes Dev. 2001;15:839–844.
48. Tevosian SG, Deconinck AE, Tanaka M, Schinke M, Litovsky SH, Izumo
S, Fujiwara Y, Orkin SH. FOG-2, a cofactor for GATA transcription
factors, is essential for heart morphogenesis and development of coronary
vessels from epicardium. Cell. 2000;101:729–739.
49. Inamoto S, Murao S, Yokoyama M, Kitazawa S, Maeda S. Isoproterenol-
induced myocardial injury resulting in altered S100A4 and S100A11
protein expression in the rat. Pathol Int. 2000;50:480–485.
50. Kitta K, Clement SA, Remeika J, Blumberg JB, Suzuki YJ. Endothelin-1
induces phosphorylation of GATA-4 transcription factor in the HL-1
atrial-muscle cell line. Biochem J. 2001;359:375–380.
51. Morimoto T, Hasegawa K, Kaburagi S, Kakita T, Wada H, Yanazume T,
Sasayama S. Phosphorylation of GATA-4 is involved in alpha
1-adrenergic agonist-responsive transcription of the endothelin-1 gene in
cardiac myocytes. J Biol Chem. 2000;275:13721–13726.
52. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA III,
Loyd JE, Nichols WC, Trembath RC. Heterozygous germline mutations
in BMPR2, encoding a TGF-beta receptor, cause familial primary pul-
monary hypertension. Nat Genet. 2000;26:81–84.
Lawrie et al 5-HT1B Receptor and SERT Regulate S100A4/Mts1 235